Dr. Chitra Neela Sambasivan, MD

Dr. Sambasivan practices at New Mexico Surgery Center Multi-Specialty - Albuquerque in Albuquerque, New Mexico.

Dr. Sambasivan's NPI, 1467665331, was assigned on May 8, 2007. Dr. Sambasivan graduated from Temple University School of Medicine in 2004. Dr. Sambasivan holds New Mexico license MD2019-0058.

Dr. Sambasivan's primary practice is New Mexico Surgery Center Multi-Specialty - Albuquerque, at 201 Cedar St Se, Suite 7650, Albuquerque, NM 87106. The practice phone is (505) 317-9444.

Dr. Sambasivan's primary practice is New Mexico Surgery Center Multi-Specialty - Albuquerque in Albuquerque, New Mexico. Dr. Sambasivan is also affiliated with Presbyterian Hospital. The medical group on file is Presbyterian Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sambasivan practices, 2 sites in all. Vendor and product names are available with a free account.

Colon and rectal surgery is Dr. Sambasivan's primary specialty in the NPI Registry, under taxonomy code 208C00000X. Dmand AI has Dr. Sambasivan's licenses on file in 3 states: New Mexico, Georgia and Texas.

CMS data shows 103 Medicare services from Dr. Sambasivan across 5 procedure codes in 2024, for 83 Medicare patients. Medicare paid $8,255 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 83 Medicare patients who saw Dr. Sambasivan in 2024. The largest group is 65 to 74, with 41 patients. 67% of them have high blood pressure, and 67% have high cholesterol. 20% are also on Medicaid. Their average risk score is 1.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sambasivan's median patient age at 60, with 51% women.

In 2024, Dr. Sambasivan wrote 218 Medicare Part D claims for 64 patients. 94% of them were for generic drugs. CMS names the drug for 177 of them, across 7 drugs with 11 or more claims each, at $2,417 in total drug cost. In 2023, CMS named 229 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Sambasivan for performance year 2024, reported as part of a group. Dr. Sambasivan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 25 procedures of colonoscopy by Dr. Sambasivan, more than 51% of the clinicians it reports for that procedure.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 4 papers to Dr. Sambasivan. The most frequent topics are Disease Models, Animal, Swine and Ascorbic Acid. Dr. Sambasivan has published most often in J Trauma. Dr. Sambasivan's most frequent co-authors are Jennifer Marie Watters, MD, Warren Charles Dorlac, MD and Stephen Francis Flaherty, MD.

CMS Open Payments shows 50 general payments to Dr. Sambasivan from 6 drug and device companies from 2019 to 2025. Education make up the largest share, 87% of the total. Intuitive Surgical, Inc. paid the most, $31,050.

Dr. Sambasivan graduated from Temple University School of Medicine in 2004.